PL3141552T3 - Pochodne tienopiryimidyny wykazujące aktywność hamującą względem kinazy białkowej - Google Patents
Pochodne tienopiryimidyny wykazujące aktywność hamującą względem kinazy białkowejInfo
- Publication number
- PL3141552T3 PL3141552T3 PL16190699T PL16190699T PL3141552T3 PL 3141552 T3 PL3141552 T3 PL 3141552T3 PL 16190699 T PL16190699 T PL 16190699T PL 16190699 T PL16190699 T PL 16190699T PL 3141552 T3 PL3141552 T3 PL 3141552T3
- Authority
- PL
- Poland
- Prior art keywords
- protein kinase
- inhibitory activity
- thienopyrimidine derivatives
- thienopyrimidine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20100008720A KR101483215B1 (ko) | 2010-01-29 | 2010-01-29 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
| EP16190699.5A EP3141552B1 (en) | 2010-01-29 | 2011-01-28 | Thienopyrimidine derivatives having inhibitory activity for protein kinase |
| EP11737311.8A EP2528920A4 (en) | 2010-01-29 | 2011-01-28 | BICYCLIC HETEROARYL DERIVATIVES WITH HEMMETIC EFFECT ON PROTEIN KINASE |
| PCT/KR2011/000615 WO2011093672A2 (en) | 2010-01-29 | 2011-01-28 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3141552T3 true PL3141552T3 (pl) | 2019-08-30 |
Family
ID=44320004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16190699T PL3141552T3 (pl) | 2010-01-29 | 2011-01-28 | Pochodne tienopiryimidyny wykazujące aktywność hamującą względem kinazy białkowej |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10112954B2 (pl) |
| EP (2) | EP3141552B1 (pl) |
| JP (1) | JP5844284B2 (pl) |
| KR (1) | KR101483215B1 (pl) |
| CN (1) | CN102741256B (pl) |
| ES (1) | ES2726882T3 (pl) |
| PL (1) | PL3141552T3 (pl) |
| TR (1) | TR201906936T4 (pl) |
| WO (1) | WO2011093672A2 (pl) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2786438C (en) * | 2010-01-29 | 2015-10-13 | Hanmi Science Co., Ltd. | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases |
| RU2735545C2 (ru) | 2010-05-20 | 2020-11-03 | Эррэй Биофарма Инк. | Макроциклические соединения в качестве ингибиторов киназы trk |
| KR101995013B1 (ko) | 2010-07-13 | 2019-07-02 | 에프. 호프만-라 로슈 아게 | Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체 |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| PE20141050A1 (es) | 2011-04-05 | 2014-08-30 | Pfizer Ltd | Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina |
| KR20130076046A (ko) * | 2011-12-28 | 2013-07-08 | 한미약품 주식회사 | 타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체 |
| RS59420B1 (sr) | 2011-12-30 | 2019-11-29 | Hanmi Pharmaceutical Co Ltd | Derivati tieno[3,2-d]pirimidina sa inhibitornom aktivnošću za proteinske kinaze |
| MX349548B (es) * | 2012-01-10 | 2017-08-02 | Hoffmann La Roche | Compuestos de tienopirimidina. |
| WO2013108809A1 (ja) * | 2012-01-19 | 2013-07-25 | 大鵬薬品工業株式会社 | ３，５－二置換ベンゼンアルキニル化合物及びその塩 |
| KR101582852B1 (ko) | 2012-05-24 | 2016-01-07 | 서울대학교 산학협력단 | 타우 단백질 매개 신경 퇴행성 질환 치료제 |
| US9611267B2 (en) | 2012-06-13 | 2017-04-04 | Incyte Holdings Corporation | Substituted tricyclic compounds as FGFR inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| JP2015531395A (ja) | 2012-10-04 | 2015-11-02 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | ピロロ［３，２−ｃ］ピリジントロポミオシン関連キナーゼ阻害剤 |
| CN103848823A (zh) * | 2012-12-06 | 2014-06-11 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| TWI649318B (zh) | 2013-04-19 | 2019-02-01 | 英塞特控股公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| RU2681849C2 (ru) | 2013-06-05 | 2019-03-13 | Си энд Си РИСЕРЧ ЛЭБОРЕТРИЗ | Гетероциклические производные и их применение |
| PT3023100T (pt) | 2013-07-18 | 2019-05-29 | Taiho Pharmaceutical Co Ltd | Fármaco antitumoral para administração intermitente de inibidor de fgfr |
| US10124003B2 (en) | 2013-07-18 | 2018-11-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for FGFR inhibitor-resistant cancer |
| PT3049417T (pt) * | 2013-07-31 | 2019-01-24 | Merck Patent Gmbh | Piridinas, pirimidinas e pirazinas, como inibidores de btk e utilizações das mesmas |
| WO2015112754A1 (en) * | 2014-01-24 | 2015-07-30 | Abbvie Inc. | Furo-3-carboxamide derivatives and methods of use |
| CR20160493A (es) | 2014-04-25 | 2016-12-16 | Pfizer | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| AU2016219822B2 (en) | 2015-02-20 | 2020-07-09 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| DK3279202T3 (da) | 2015-03-31 | 2020-08-17 | Taiho Pharmaceutical Co Ltd | Krystal af 3,5-disubstitueret benzenalkynylforbindelse |
| PT3322706T (pt) | 2015-07-16 | 2021-03-08 | Array Biopharma Inc | Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret |
| CA2993022A1 (en) * | 2015-07-20 | 2017-01-26 | Taipei Medical University | Chlorobenzene substituted azaaryl compounds |
| EP3365335B1 (en) | 2015-10-23 | 2024-02-14 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| KR20220110859A (ko) | 2016-03-04 | 2022-08-09 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| IL274963B2 (en) | 2017-11-30 | 2024-10-01 | Hanmi Pharmaceutical Co Ltd | THIENO[3,2-d]PYRIMIDINE COMPOUND HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE |
| CN107973727B (zh) * | 2017-12-11 | 2020-04-17 | 中山大学 | 间二取代苯酚化合物及其制备方法与抗结核菌应用 |
| WO2019143991A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS |
| WO2019143977A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| JP6997876B2 (ja) | 2018-01-18 | 2022-02-04 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物 |
| MX2020009762A (es) | 2018-03-19 | 2021-01-08 | Taiho Pharmaceutical Co Ltd | Composicion farmaceutica que incluye alquil sulfato de sodio. |
| TW201946630A (zh) | 2018-05-04 | 2019-12-16 | 美商英塞特公司 | Fgfr抑制劑之鹽 |
| ES2991427T3 (es) | 2018-05-04 | 2024-12-03 | Incyte Corp | Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas |
| CA3111984A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| CN113474337A (zh) | 2018-12-19 | 2021-10-01 | 奥瑞生物药品公司 | 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物 |
| JP2022515198A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| CN112110937B (zh) * | 2019-06-20 | 2022-03-22 | 四川大学 | 一种噻吩并[2,3-d]嘧啶-4(3h)-酮衍生物及其制备方法和用途 |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| GEAP202415945A (en) | 2019-10-14 | 2024-04-25 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US20230115945A1 (en) | 2019-12-30 | 2023-04-13 | Tyra Biosciences, Inc. | Aminopyrimidine compounds |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4008716A1 (en) * | 2020-12-04 | 2022-06-08 | Martin-Luther-Universität Halle-Wittenberg | Novel inhibitors of insulin-like growth factor 2 mrna binding proteins |
| MX2023007793A (es) | 2020-12-30 | 2023-09-22 | Tyra Biosciences Inc | Compuestos de indazol como inhibidores de cinasas. |
| MX2023009954A (es) | 2021-02-26 | 2023-11-09 | Tyra Biosciences Inc | Compuestos de aminopirimidina y métodos de uso de estos. |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| AR126101A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| CN114524826A (zh) * | 2022-02-18 | 2022-05-24 | 郑州猫眼农业科技有限公司 | 7-溴-4-氯噻吩并[3,2-d]嘧啶的制备工艺 |
| TW202416961A (zh) | 2022-06-29 | 2024-05-01 | 美商泰拉生物科學公司 | 吲唑化合物 |
| EP4547670A1 (en) | 2022-06-29 | 2025-05-07 | Tyra Biosciences, Inc. | Polymorphic compounds and uses thereof |
| WO2024138112A1 (en) | 2022-12-22 | 2024-06-27 | Tyra Biosciences, Inc. | Indazole compounds |
| WO2025129014A1 (en) | 2023-12-15 | 2025-06-19 | Tyra Biosciences, Inc. | Indazole compounds for the treatment of cancer |
| WO2025222097A1 (en) | 2024-04-19 | 2025-10-23 | Tyra Biosciences, Inc. | Indazole-based protac degraders and their anticancer activity |
| WO2026035809A1 (en) | 2024-08-06 | 2026-02-12 | Tyra Biosciences, Inc. | Indazole compounds for the treatment of cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR004010A1 (es) * | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| WO1997049706A1 (en) * | 1996-06-25 | 1997-12-31 | Novartis Ag | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF |
| US6281227B1 (en) * | 1996-12-13 | 2001-08-28 | Aventis Pharma Deutschland Gmbh | Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds |
| GB9906566D0 (en) | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
| ATE489384T1 (de) | 2002-05-06 | 2010-12-15 | Vertex Pharma | Thiadiazole oder oxadiazole und ihre verwendung als jak proteinkinaseinhibitoren |
| DE60333546D1 (de) | 2003-05-06 | 2010-09-09 | Univ Palackeho | PyrazoloÄ4,3-DÜpyrimidines, verfahren zur ihre herstellung und deren verwendung |
| BRPI0511295A (pt) * | 2004-05-18 | 2007-12-04 | Schering Corp | 2-quinolil-oxazóis substituìdos úteis como inibidores de pde4 |
| BRPI0511512A (pt) | 2004-05-27 | 2007-12-26 | Pfizer Prod Inc | derivados pirrolpirimidina úteis no tratamento do cáncer |
| US20060004002A1 (en) * | 2004-07-02 | 2006-01-05 | Thomas Thrash | Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors |
| US7514463B2 (en) * | 2004-08-20 | 2009-04-07 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
| SI1838718T1 (sl) * | 2005-01-10 | 2011-08-31 | Pfizer | Pirolopirazoli, zmogljivi inhibitorji kinaze |
| WO2006124874A2 (en) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| US20090247554A1 (en) * | 2006-03-30 | 2009-10-01 | Takeda San Diego, Inc. | Kinase inhibitors |
| CN101466716A (zh) | 2006-04-07 | 2009-06-24 | 德维洛根股份公司 | 用于药物组合物的具有mnkl/mnk2抑制活性的噻吩并嘧啶 |
| WO2008082839A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
| WO2009013545A2 (en) | 2007-07-26 | 2009-01-29 | Astrazeneca Ab | Chemical compounds |
| CN102712646A (zh) * | 2009-08-28 | 2012-10-03 | 阵列生物制药公司 | Raf抑制剂化合物及其使用方法 |
| KR101995013B1 (ko) * | 2010-07-13 | 2019-07-02 | 에프. 호프만-라 로슈 아게 | Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체 |
-
2010
- 2010-01-29 KR KR20100008720A patent/KR101483215B1/ko active Active
-
2011
- 2011-01-28 US US13/575,799 patent/US10112954B2/en active Active
- 2011-01-28 JP JP2012551091A patent/JP5844284B2/ja active Active
- 2011-01-28 TR TR2019/06936T patent/TR201906936T4/tr unknown
- 2011-01-28 ES ES16190699T patent/ES2726882T3/es active Active
- 2011-01-28 EP EP16190699.5A patent/EP3141552B1/en active Active
- 2011-01-28 EP EP11737311.8A patent/EP2528920A4/en not_active Withdrawn
- 2011-01-28 WO PCT/KR2011/000615 patent/WO2011093672A2/en not_active Ceased
- 2011-01-28 CN CN201180007509.3A patent/CN102741256B/zh active Active
- 2011-01-28 PL PL16190699T patent/PL3141552T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3141552B1 (en) | 2019-04-17 |
| KR20110088960A (ko) | 2011-08-04 |
| US10112954B2 (en) | 2018-10-30 |
| EP2528920A2 (en) | 2012-12-05 |
| TR201906936T4 (tr) | 2019-06-21 |
| EP2528920A4 (en) | 2013-08-07 |
| KR101483215B1 (ko) | 2015-01-16 |
| ES2726882T3 (es) | 2019-10-10 |
| CN102741256B (zh) | 2015-12-02 |
| US20120302567A1 (en) | 2012-11-29 |
| CN102741256A (zh) | 2012-10-17 |
| WO2011093672A3 (en) | 2012-01-05 |
| JP2013518098A (ja) | 2013-05-20 |
| JP5844284B2 (ja) | 2016-01-13 |
| WO2011093672A2 (en) | 2011-08-04 |
| EP3141552A1 (en) | 2017-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3141552T3 (pl) | Pochodne tienopiryimidyny wykazujące aktywność hamującą względem kinazy białkowej | |
| EP2710018B8 (en) | Macrocyclic compounds as protein kinase inhibitors | |
| EP3409278B8 (en) | Heterocyclic protein kinase inhibitors | |
| ZA201405583B (en) | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity for protein kinases | |
| ZA201402164B (en) | Protein kinase inhibitors | |
| EP2694517A4 (en) | PROTEIN KINASE INHIBITORS | |
| IL247405A0 (en) | Apoptosis signal-regulating kinase inhibitors | |
| EP2552208A4 (en) | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | |
| EP2552214A4 (en) | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | |
| EP2552211A4 (en) | INDAZOLYL-PYRIMIDINE AS KINASEHEMMER | |
| SI2531501T1 (sl) | Inhibitorji kinaze-1, ki regulirajo signal apoptoze | |
| ZA201306855B (en) | Protein kinase inhibitors | |
| IL228103A0 (en) | Amino-quinolines as kinase inhibitors | |
| GB201009731D0 (en) | Kinase inhibitors | |
| HU0900798D0 (en) | 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity | |
| IL230504A0 (en) | Selective protein kinase inhibitors | |
| EP2571884A4 (en) | SELECTIVE MTOR KINASE HEMMER | |
| EP2870158A4 (en) | PROTEIN KINASE INHIBITORS | |
| GB201109094D0 (en) | Indexable insert | |
| EP2855484A4 (en) | PROTEIN KINASE INHIBITORS | |
| EP2895166A4 (en) | AMINOISOQUINOLINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | |
| EP2838531A4 (en) | INDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | |
| IL221065A (en) | General antiviral peptides for protein kinase inhibition | |
| PL2646448T3 (pl) | Makrocykliczne inhibitory kinazy | |
| HK1195057A (en) | Protein kinase inhibitors |